| アブストラクト | BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), commonly used antihypertensive drugs, may have a protective effect against depression in older individuals, but evidence in humans is limited. AIMS: We evaluated the risk of depression, among older individuals with hypertension, comparing ACE or ARB initiators to thiazide(-like) diuretic initiators. Thiazide(-like) diuretics were used as control because these drugs are not associated with mood disorders. METHODS: We used a propensity score-matched new user cohort design with routinely collected data from general practices in England from the Clinical Practice Research Datalink database. We matched 12,938 pairs of new users of ACEIs/ARBs and thiazide(-like) diuretics with hypertension (mean age 67.6 years; 54.7% women). Follow-up time started on the date of drug initiation and ended on the date of treatment discontinuation plus 30 days, or switch to a comparator, occurrence of a study event, death, date of patient's transfer out of practice, or end of the study period. The primary outcome was a composite endpoint of treated depression and nonfatal and fatal self-harm. RESULTS/OUTCOMES: Compared to the thiazide(-like) diuretic group, ACEIs/ARBs use was not associated with a lower risk of the primary outcome (hazard ratio 0.96 (95% confidence interval: 0.79; 1.15)). Results did not differ according to lipophilicity, duration of use, and average daily dose, or class (ACEIs or ARBs). CONCLUSIONS/INTERPRETATION: New use of ACEIs or ARBs is not associated with a lower risk of depression among individuals with hypertension. |
|---|
| ジャーナル名 | Journal of psychopharmacology (Oxford, England) |
|---|
| 投稿日 | 2022/4/8 |
|---|
| 投稿者 | van Sloten, Thomas T; Souverein, Patrick C; Stehouwer, Coen DA; Driessen, Johanna Hm |
|---|
| 組織名 | Department of Internal Medicine, Maastricht University Medical Center+,;Maastricht, The Netherlands.;School for Cardiovascular Diseases (CARIM), Maastricht University, Maastricht,;The Netherlands.;Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of;Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.;Department of Clinical Pharmacy and Toxicology, Maastricht University Medical;Center+, Maastricht, The Netherlands.;School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht;University, Maastricht, The Netherlands. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35388727/ |
|---|
